Quest Diagnostics (NYSE: DGX): Q1 2018 Earnings Overview

“We delivered strong revenue and earnings growth in the first quarter. We grew revenue 3.7 percent despite severe winter weather and the impact of lower Medicare reimbursement under PAMA. Earnings growth was driven by our continued strong execution as well as the benefits of tax reform. Our two-point strategy of accelerating growth and driving operational excellence continues to produce results.”

Steve Rusckowski
Chairman, President and CEO

Key Stats

16 consecutive quarters of year-on-year equivalent revenue growth

Q1 2018 vs. 2017

Revenues of
$1.88 billion-up 3.7%

Reported diluted EPS of
$1.27-up 9.5%

Adjusted EPS of
$1.52-up 24.6%

Tax Reform

$

Quest is a significant beneficiary of lower corporate tax rates which will enable us to **grow and invest** in our business and our people.

We will realize
~$180million
in tax savings on an adjusted basis.

Reinvesting
~$75million
before tax back in the business and our people.

Q1 Highlights

med fusion
clin-labs • clin-trials

integration creates a center of excellence in precision medicine to guide community oncologists' treatment of patients with cancer.

6 Walmart Quest locations in Walmart continue to perform very well.

Acquisition of MEDXM

Customers are excited that Quest can help them close critical gaps in care using **mobile health care professionals** to reach our patients when and where it's most convenient.